# Impact of ECMO Cannula Chlorhexidine-impregnated Dressings to Decrease Extracorporeal Membrane Oxygenation-cannula Related Infection Rate

Study · id `cardio:ct-nct05750576` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05750576](<https://clinicaltrials.gov/study/NCT05750576>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05750576

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.

## Technical summary

Registry record NCT05750576. Randomized; no masking; primary purpose other. Start 2023-06-15 (actual); primary completion 2025-06-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 270 participants (enrolled count; ClinicalTrials.gov record NCT05750576, source copy `cardio:ctgov-nct05750576-2025-11-24`, retrieved 2026-10-31)
- Started: 2023-06-15 (actual) (ClinicalTrials.gov record NCT05750576, source copy `cardio:ctgov-nct05750576-2025-11-24`, retrieved 2026-10-31)
- Primary completion: 2025-06-20 (actual) (ClinicalTrials.gov record NCT05750576, source copy `cardio:ctgov-nct05750576-2025-11-24`, retrieved 2026-10-31)
- Completion: 2025-06-20 (actual) (ClinicalTrials.gov record NCT05750576, source copy `cardio:ctgov-nct05750576-2025-11-24`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT05750576, source copy `cardio:ctgov-nct05750576-2025-11-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05750576-2025-11-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Impact of ECMO Cannula Chlorhexidine-impregnated Dressings to Decrease Extracorporeal Membrane Oxygenation-cannula Related Infection Rate
- Acronym: DRESSING-ECMO
- Condition: Cardiogenic Shock
- Condition: Extracorporeal Membrane Oxygenation Complication
- Condition: Acute Respiratory Distress Syndrome
- Condition: Infections
- Intervention (Device): Chlorhexidine-impregnated dressings
- Intervention (Device): Non impregnated dressings
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 01637a94b14543366575662de3d616bff0fd45738ca0146a50f5842b46c438ec
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
